Dataset: Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer [mRNA]
To perform an integrative profile of human pancreatic cancer (PDAC) to identify prognosis-significant genes and their related pathways. A...
To perform an integrative profile of human pancreatic cancer (PDAC) to identify prognosis-significant genes and their related pathways. A concordant survival-based whole genome in silico array analysis of DNA copy number, and mRNA & micro RNA (miRNA) expression in 25 early stage PDAC was performed. A novel composite score simultaneously integrated gene expression with regulatory mechanisms to identify the signature genes with the most levels of prognosis-significant evidence. The predominant signaling pathways were determined via a pathway-based approach. Independent patient cohorts (n= 150 and 42) were then used as in vitro validation of the array findings. We find that EGFR, SRC signaling, and PI3K/AKT pathway activation are strongly linked to clinical disease progression. Furthermore, we identify two discrete subsets of pancreatic tumors characterized by either SRC or PI3K/AKT signaling that may dictate variable responses to targeted therapy. 42 human PDAC tumors and 7 non-malignant pancreas samples snap-frozen at the time of surgery were chosen. Representative H&E sections of each were evaluated by a practicing gastrointestinal pathologist to confirm diagnosis and determine relative percentage of malignant cells. Samples with tumor cell content >30% were chosen for final multi-platform analysis (N=25). Human pancreatic samples were profiled on Affymetrix HGU133 Plus 2 arrays per manufacturer's instructions.
- Species:
- human
- Samples:
- 32
- Source:
- E-GEOD-32676
- Updated:
- Dec.12, 2014
- Registered:
- Sep.16, 2014
Sample | GRADE | DISEASE STATUS | TUMOR CONTENT | AJCC STAGE |
---|---|---|---|---|
GSM811004 | 2.0 | pancreatic cancer | 90.0 | 2B |
GSM811005 | 2.0 | pancreatic cancer | 90.0 | 1B |
GSM811006 | 1.0 | pancreatic cancer | 80.0 | 2A |
GSM811007 | 2.0 | pancreatic cancer | 80.0 | 2B |
GSM811007 | 2.0 | pancreatic cancer | 80.0 | 2B |
GSM811009 | 3.0 | pancreatic cancer | 80.0 | 2B |
GSM811010 | 2.0 | pancreatic cancer | 75.0 | 1B |
GSM8110 | 3.0 | pancreatic cancer | 75.0 | 2B |
GSM8110 | 3.0 | pancreatic cancer | 75.0 | 2B |
GSM811013 | 2.0 | pancreatic cancer | 70.0 | 2B |
GSM811014 | 2.0 | pancreatic cancer | 60.0 | 2B |
GSM811015 | 2.0 | pancreatic cancer | 60.0 | 2A |
GSM811016 | 3.0 | pancreatic cancer | 60.0 | 2B |
GSM811015 | 2.0 | pancreatic cancer | 60.0 | 2A |
GSM811018 | 3.0 | pancreatic cancer | 50.0 | 2A |
GSM811019 | 2.0 | pancreatic cancer | 50.0 | 2B |
GSM811019 | 2.0 | pancreatic cancer | 50.0 | 2B |
GSM81102 | 3.0 | pancreatic cancer | 50.0 | 2B |
GSM811022 | 2.0 | pancreatic cancer | 45.0 | 2A |
GSM811023 | 2.0 | pancreatic cancer | 40.0 | 2B |
GSM811023 | 2.0 | pancreatic cancer | 40.0 | 2B |
GSM811025 | 3.0 | pancreatic cancer | 35.0 | 2B |
GSM811026 | 2.0 | pancreatic cancer | 35.0 | 2B |
GSM811026 | 2.0 | pancreatic cancer | 35.0 | 2B |
GSM811028 | 2.0 | pancreatic cancer | 35.0 | 2A |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |
GSM811029 | nan | non-malignant pancreas | nan | nan |